The Marlborough, MA-based company said it will have a limited launch of the Watchman FLX Left Atrial Appendage Closure (LAAC) technology and a broader launch in 4Q20.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,